The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
Microbial systems are a black box. We created Microbial INtelligence Explorer to “MINE” their secrets• Microbiotica Raises $48 Million Series C to Advance Pipeline into Phase 2 Clinical Development• Prokarium: Leading the Evolution of Bacterial Immunotherapy, the Next Frontier in Cancer Treatment• Claude Discovers Novel Enzyme System with CRISPR-like Repeats• New Clinical Study Aims to Find Out if FMT capsules could help better manage anorexia• MaaT Pharma Provides Update on MaaT013 (Xervyteg®) Potential Development Plan Following CHMP Negative Opinion After Re-examination•

Category: Infectious Disease & AMR

Phage therapy: A model to predict its efficacy against pathogenic bacteria
Infectious Disease & AMR

Phage therapy: A model to predict its efficacy against pathogenic bacteria

MAY 23, 2022
Researchers use virus to fight bacterial infection clearing way for life-saving lung transplant
Infectious Disease & AMR

Researchers use virus to fight bacterial infection clearing way for life-saving lung transplant

MAY 17, 2022
Study finds how Acinetobacter baumannii survives without water on hospital surfaces
Infectious Disease & AMR

Study finds how Acinetobacter baumannii survives without water on hospital surfaces

MAY 5, 2022
Pherecydes Pharma Announces the First International Approval of a Compassionate Treatment With Its Phages
Infectious Disease & AMR

Pherecydes Pharma Announces the First International Approval of a Compassionate Treatment With Its Phages

MAY 3, 2022
Adaptive Phage Therapeutics Extends Series B to $61 million with Addition of The AMR Action Fund
Finance

Adaptive Phage Therapeutics Extends Series B to $61 million with Addition of The AMR Action Fund

APR 4, 2022
A new photoactive viral vector for anti-cancer therapy has been developed
GMO & Synbio

A new photoactive viral vector for anti-cancer therapy has been developed

MAR 15, 2022
Pherecydes Pharma and BIOASTER Join Forces in the Treatment of Bacteremia
Finance

Pherecydes Pharma and BIOASTER Join Forces in the Treatment of Bacteremia

MAR 14, 2022
Researchers discover unique lysin capable of killing deadly multidrug-resistant bacteria
Infectious Disease & AMR

Researchers discover unique lysin capable of killing deadly multidrug-resistant bacteria

FEB 20, 2022
Protecting and Preserving the Intestinal Microbiome from Antibiotic-induced Dysbiosis with DAV132
Biotech Showcase

Protecting and Preserving the Intestinal Microbiome from Antibiotic-induced Dysbiosis with DAV132

FEB 17, 2022
Armata Pharmaceuticals Announces $45 Million Investment to Support Advancement of the Company’s Bacteriophage Development
Finance

Armata Pharmaceuticals Announces $45 Million Investment to Support Advancement of the Company’s Bacteriophage Development

FEB 10, 2022
Publication of ECOSPOR lll Phase 3 Study Data Evaluating SER-109 in Recurrent C. Difficile Infection
Clinical & Manufacturing

Publication of ECOSPOR lll Phase 3 Study Data Evaluating SER-109 in Recurrent C. Difficile Infection

JAN 24, 2022